Hainan Haiyao Co Ltd

The brain-computer interface concept continued its strong momentum in early trading on July 28, with Innovative Medical hitting a 4-day 3-board streak, and Hainan Haiyao, Yanshan Technology, and Thalys Medical hitting the daily limit up. The core catalyst for this rally came from an overseas commercialization milestone: US startup Science Corp.'s retinal chip PRIMA has received EU CE certification, becoming the world's first brain-computer interface device to obtain this certification, and has been approved for sale in 30 European countries. On the domestic front, a Chinese research team unveiled a new EEG signal acquisition device, achieving the world's first cross-regional synchronous EEG signal collection from over a thousand people. The implantable brain-computer interface hand motor function compensation system NEO issued its first prescription in Shanghai and completed the world's first implant surgery. Capital market enthusiasm is high, with total financing in China's brain-computer interface sector exceeding 4.4 billion yuan from January to May 2026, more than doubling the full-year total of last year. A research report from Zheshang Securities pointed out that the market size for brain-computer interface demand in China's serious medical field alone could reach 20 to 60 billion yuan, while the global market is projected to grow from 2.41 billion dollars in 2025 to 12.11 billion dollars in 2035, at a compound annual growth rate of 15.8 percent. Southwest Securities judged that 2026 will be the first year of mass production for brain-computer interfaces, with the industry at the tail end of the introduction phase and on the eve of an explosion.

On the morning of July 27, A-share brain-computer interface concept stocks broke out strongly, with stocks in the sector rising collectively during the session. Chuangxin Medical hit a three-day two-board pattern, Aipeng Medical recorded a 20 percent daily limit up, Hainan Haiyao recorded a 10 percent daily limit up and hit a four-day two-board pattern, while Meihao Medical, New Journey, Yingkang Life, Xiangyu Medical, and Sanbo Brain Hospital and other concept stocks followed the rally. On the news front, a Chinese research team recently released a new type of EEG signal acquisition device, achieving for the first time globally the synchronous collection of EEG signals from over a thousand people across different regions. This breakthrough marks a key step forward in neural large model training and general brain-computer interface technology research and development. Kaiyuan Securities stated that it remains bullish on innovative drugs and their industry chain, as well as national strategic emerging industries such as AI, brain-computer interfaces, and biomanufacturing.

China's A-share market underwent volatile adjustments today, with the Shanghai Composite Index falling 1.85 percent and losing the 3,900-point level. However, the traditional Chinese medicine sector surged against the market, with Pien Tze Huang and ZBD Pharma hitting their daily limit up in the afternoon. The pharmaceutical and biological industry saw a net inflow of over 5 billion yuan in main funds, and the TCM sector index rose more than 3 percent at one point during the session, marking seven consecutive positive daily candlesticks. Harbin Pharmaceutical Group locked in its fifth straight daily limit up, while Hainan Haiyao achieved its second consecutive daily limit up. Chip stocks, on the other hand, suffered a broad sell-off, with the semiconductor sector index plunging more than 5 percent. Companies such as JCET and Demingli hit limit down in batches. Global chip stocks also faced heavy selling, with South Korea's SK Hynix tumbling 11.53 percent and Japan's Kioxia plummeting 15.03 percent. On the news front, the State Council approved the 15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine, and the 2026 edition of the National Essential Medicines List added 48 new proprietary Chinese medicines.